Drugs / Anti-NY ESO-1 T-cell receptor PBL
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00670748 | May 2008 → Jun 2016 | metastatic malignant neoplasm, metastatic melanoma, renal cell carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-NY ESO-1 T-cell receptor PBL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00670748 ↗ |
| Route | Intravenous | “cells (1x10e8 to 1x10e11)will be infused intravenously” NCT00670748 ↗ |